-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VQGtwDTyWYAgTvcJ0iA8xb8FLmXMKjxTZLcNlyNmLkku1gfeZD1tfiN2rJjM9CL4 97l8NOPyrkXu/f6TvIwowg== 0000912057-97-002509.txt : 19970203 0000912057-97-002509.hdr.sgml : 19970203 ACCESSION NUMBER: 0000912057-97-002509 CONFORMED SUBMISSION TYPE: SC 13E3/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970131 SROS: NONE GROUP MEMBERS: NOVARTIS BIOTECH HOLDING CORP. GROUP MEMBERS: NOVARTIS INC GROUP MEMBERS: SYSTEMIX, INC. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: SYSTEMIX INC /DE CENTRAL INDEX KEY: 0000876428 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 770193369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13E3/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-41866 FILM NUMBER: 97514815 BUSINESS ADDRESS: STREET 1: 3155 PORTER DRIVE CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 4158564901 MAIL ADDRESS: STREET 1: 3155 PORTER DR CITY: PALO ALTO STATE: CA ZIP: 94304 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: NOVARTIS INC CENTRAL INDEX KEY: 0001030617 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: SC 13E3/A BUSINESS ADDRESS: STREET 1: SCHWARZWALDALLEE 215 STREET 2: 4002 BASEL CITY: SWITZERLAND BUSINESS PHONE: 2128302413 MAIL ADDRESS: STREET 1: SCHWARZWALDALLEE 215 STREET 2: 4002 BASEL CITY: SWITZERLAND STATE: V8 SC 13E3/A 1 SCHEDULE 13E-3/A - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 -------------------------- SCHEDULE 13E-3 (AMENDMENT NO. 1) RULE 13E-3 TRANSACTION STATEMENT (PURSUANT TO SECTION 13(E) OF THE SECURITIES EXCHANGE ACT OF 1934) SYSTEMIX, INC. (Name of the Issuer) SYSTEMIX, INC. NOVARTIS BIOTECH HOLDING CORP. NOVARTIS INC. (Name of Person(s) Filing Statement) COMMON STOCK, PAR VALUE $.01 PER SHARE (Title of Class of Securities) 871872-10-7 (CUSIP Number of Class of Securities) ROBERT L. THOMPSON, JR., ESQ. IRIS BREST, ESQ. NOVARTIS BIOTECH HOLDING CORP. SYSTEMIX, INC. NOVARTIS INC. 3155 PORTER DRIVE C/O NOVARTIS CORPORATION PALO ALTO, CALIFORNIA 94304 608 FIFTH AVENUE, 10TH FLOOR (415) 813-4119 NEW YORK, NEW YORK 10020 (212) 830-2401
(Name, Address and Telephone Number of Persons Authorized to Receive Notices and Communications on Behalf of Person(s) Filing Statement) WITH COPIES TO: DAVID W. HELENIAK, ESQ. MORRIS J. KRAMER, ESQ. SHEARMAN & STERLING SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP 599 LEXINGTON AVENUE 919 THIRD AVENUE NEW YORK, NEW YORK 10022 NEW YORK, NEW YORK 10022 (212) 848-4000 (212) 735-3000
This statement is filed in connection with (check the appropriate box): a. / / The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under the Securities Exchange Act of 1934. b. / / The filing of a registration statement under the Securities Act of 1933. c. /X/ A tender offer. d. / / None of the above. Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: [ ] - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- This Amendment No. 1 to the Rule 13e-3 Transaction Statement on Schedule 13E-3 (this "Amendment") relates to the offer by Novartis Biotech Holding Corp., a Delaware corporation ("Purchaser") and an indirect wholly owned subsidiary of Novartis Inc., a company organized under the laws of Switzerland ("Parent"), to purchase all outstanding shares of Common Stock, par value $.01 per share (the "Common Stock"), of SyStemix, Inc. (the "Shares"), a Delaware corporation, at a price of $19.50 per Share, net to the seller in cash, upon the terms and subject to the conditions set forth in Purchaser's Offer to Purchase dated January 17, 1997 and in the related Letter of Transmittal. ITEM 16. Additional Information. Item 16 is hereby amended and supplemented as follows: Parent and the other defendants have reached an agreement with the plaintiffs to settle the consolidated action captioned In Re SyStemix, Inc. Shareholder Litigation, Consolidated C.A. 15014. If this agreement is accepted and approved by the Delaware Chancery Court, the case would be dismissed with prejudice. As a part of such a settlement and dismissal, Parent and the other defendants would not object to a court award of attorneys' fees and expenses to counsel for plaintiffs of $385,000 or less. SIGNATURES After due inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: January 30, 1997 NOVARTIS BIOTECH HOLDING CORP. By /s/ Robert L. Thompson, Jr. ----------------------------------------- Name: Robert L. Thompson, Jr. Title: Vice President NOVARTIS INC. By /s/ Robert L. Thompson, Jr. ----------------------------------------- Name: Robert L. Thompson, Jr. Title: Attorney-in-Fact SIGNATURE After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 30, 1997 SYSTEMIX, INC. By /s/ John J. Schwartz ----------------------------------------- Name: John J. Schwartz, Ph.D. Title: President and Chief Executive Officer -----END PRIVACY-ENHANCED MESSAGE-----